Mechanisms of Mitochondrial Dysfunction in Alzheimer’s Disease

Molecular Neurobiology

Volumn 53, Issue 9, 2016, Pages 6078-6090

  Cadonic, Chris ^a,b   Sabbir, Mohammad Golam ^a   Albensi, Benedict C ^a,b  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Alzheimer s disease; Electron transport chain; Mitochondria; Mitochondrial dysfunction; Review

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOCHROME; FLAVINE MONONUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCING AGENT; TAU PROTEIN; UBIQUINONE;

ALZHEIMER DISEASE; BIOENERGY; CATABOLISM; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; ENDOSYMBIOSIS; HUMAN; INFLAMMATION; NEUROFIBRILLARY TANGLE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; RESPIRATORY CHAIN; REVIEW; ANIMAL; DISEASE EXACERBATION; ENERGY METABOLISM; METABOLISM; MITOCHONDRION; PATHOLOGY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; DISEASE PROGRESSION; ELECTRON TRANSPORT; ENERGY METABOLISM; HUMANS; MITOCHONDRIA;

EID: 84946123860     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9515-5     Document Type: Review

References (45)

1. Nelson D, Cox M (2004) Lehninger principles of biochemistry, 4th edn. W.H. Freeman
2. Scheffler I (2007) Mitochondria, 2nd edn. Wiley
3. Nicholls D, Ferguson S (2013) Bioenergetics, 4th edn. Elsevier
4. Mannella CA (2006) Structure and dynamics of the mitochondrial inner membrane cristae. Biochim Biophys Acta 1763(5–6):542–548
5. Zharova TV, Vinogradov AD (1997) A competitive inhibition of the mitochondrial NADH-ubiquinone oxidoreductase (complex I) by ADP-ribose. Biochim Biophys Acta 1320(3):256–264
6. Watabe M, Nakaki T (2008) Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells. Mol Pharmacol 74(4):933–940
7. Muller FL, Liu Y, Abdul-Ghani MA, Lustgarten MS, Bhattacharya A, Jang YC, Van Remmen H (2008) High rates of superoxide production in skeletal-muscle mitochondria respiring on both complex I- and complex II-linked substrates. Biochem J 409(2):491–499
8. Dairaku N, Kato K, Honda K, Koike T, Iijima K, Imatani A, Sekine H, Ohara S et al (2004) Oligomycin and antimycin a prevent nitric oxide-induced apoptosis by blocking cytochrome C leakage. J Lab Clin Med 143(3):143–151
9. Nakata M, Ishiyama T, Akamatsu S, Hirose Y, Maruoka H, Suzuki R, Tatsuta K (1995) Synthetic studies on oligomycins. Synthesis of the oligomycin B spiroketal and polypropionate portions. Bull Chem Soc Jpn 68(3):967–989
10. Jastroch M, Divakaruni AS, Mookerjee S, Treberg JR, Martin D (2011) “NIH Public Access,” 53–67
11. Arnáiz E, Almkvist O (2003) Neuropsychological features of mild cognitive impairment and preclinical Alzheimer’s disease. Acta Neurol Scand Suppl 179:34–41
12. Kurz HFA (1999) “Clinical features of Alzheimer’s disease,”. 288–290
13. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63(2):168–174
14. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) “The cholinergic hypothesis of Alzheimer’s disease: a review of progress”.137–147
15. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12(10):383–388
16. Mudher A, Lovestone S (2002) Alzheimer’s disease—do tauists and baptists finally shake hands? Trends Neurosci 25(1):22–26
17. Hashimoto M, Rockenstein E, Crews L, Masliah E (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neuromol Med 4(1–2):21–36
18. Hauptmann S, Keil U, Scherping I, Bonert A, Eckert A, Müller WE (2006) Mitochondrial dysfunction in sporadic and genetic Alzheimer’s disease. Exp Gerontol 41(7):668–673
19. Chen X, Yan SD (2006) Mitochondrial abeta: a potential cause of metabolic dysfunction in Alzheimer’s disease. IUBMB Life 58(12):686–694
20. Lunnon K, Ibrahima Z, Proitsi P, Lourdusamy A, Newhouse S, Sattlecker M, Furney S, Saleem M et al (2012) Mitochondrial dysfunction and immune activation are detectable in early alzheimer’s disease blood. J Alzheimers Dis 30(3):685–710
21. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Perspective 81(2):741–767
22. García-Escudero V, Martín-Maestro P, Perry G, Avila J (2013) “Deconstructing mitochondrial dysfunction in alzheimer disease”. Oxidative Med Cell Longev 2013
23. Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, Zhu X (2010) Alzheimer’s disease: diverse aspects of mitochondrial malfunctioning. Int J Clin Exp Pathol 3(6):570–581
24. Swerdlow RH, Burns JM, Khan SM (2014) The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta Mol basis Dis 1842(8):1219–1231
25. Swerdlow RH, Khan SM (2004) A ‘mitochondrial cascade hypothesis’ for sporadic Alzheimer’s disease. Med Hypotheses 63(1):8–20
26. Esteves AR, Arduino DM (2009) “Mitochondrial metabolism in age-related neurodegenerative disorders: Alzheimer’s and Parkinson’s revisited.” In: Svensson OL (ed.) Mitochondria: structure, functions and dysfunctions
27. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787–795
28. Zhu X, Perry G, Smith MA, Wang X (2013) Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis 33(Suppl 1):S253–S262
29. Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, Wilson JM, DiStefano LM et al (1992) Brain cytochrome oxidase in Alzheimer’s disease. J Neurochem 59(2):776–779
30. Mutisya EM, Bowling AC, Beal MF (1994) Cortical cytochrome oxidase activity is reduced in Alzheimer’s disease. J Neurochem 63(6):2179–2184
31. Shoffner JM (1997) Oxidative phosphorylation defects and Alzheimer’s disease. Neurogenetics 1(1):13–19
32. Seelert H, Dani DN, Dante S, Hauß T, Krause F, Schäfer E, Frenzel M, Poetsch A et al (2009) From protons to OXPHOS supercomplexes and Alzheimer’s disease: structure-dynamics-function relationships of energy-transducing membranes. Biochim Biophys Acta Bioenerg 1787(6):657–671
33. Cardoso S, Santana I, Swerdlow R, Oliveira C (2004) Mitochondria dysfunction of Alzheimer’s disease cybrids enhances Abeta toxicity. J Neurochem 89(6):1417–1426
34. Sterniczuk R, Dyck RH, Laferla FM, Antle MC (2010) Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: part 1. Circadian changes. Brain Res 1348:139–148
35. Pereira C, Santos MS, Oliveira C (1999) Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants. Neurobiol Dis 6(3):209–219
36. Wilkins HM, Carl SM, Weber SG, Ramanujan SA, Festoff BW, Linseman DA, Swerdlow RH (2014) “Mitochondrial lysates induce inflammation and alzheimer’s disease-relevant changes in microglial and neuronal cells.” J Alzheimers Dis
37. De Felice FG, Ferreira ST (2014) Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63(7):2262–2272
38. Cardoso S, Santos S, Swerdlow RH, Oliveira CR (2001) Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J 15(8):1439–1441
39. Wang X, Wang W, Li L, Perry G, Lee H, Zhu X (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta Mol basis Dis 1842(8):1240–1247
40. Aliev G, Obrenovich ME, Tabrez S, Jabir NR, Reddy VP, Li Y, Burnstock G, Cacabelos R, Kamal MA (2013) “Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion.” Oxidative Med Cell Longev 2013
41. Ngo H, Tortorella SM, Ververis K, Karagiannis TC (2014) The Warburg effect: molecular aspects and therapeutic possibilities. Mol Biol Rep 42(4):825–834
42. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, Morris JC, Raichle ME et al (2010) Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. Proc Natl Acad Sci U S A 107(41):17763–17767
43. Coskun PE, Beal MF, Wallace DC (2004) Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A 101(29):10726–10731
44. Hamblet NS, Ragland B, Ali M, Conyers B, Castora FJ (2006) Mutations in mitochondrial-encoded cytochrome c oxidase subunits I, II, and III genes detected in Alzheimer’s disease using single-strand conformation polymorphism. Electrophoresis 27(2):398–408
45. Burté F, Carelli V, Chinnery PF, Yu-Wai-Man P (2014) Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat Rev Neurol 11(1):11–24